Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors.
Authors
Jian Li
Beijing Cancer Hospital, Beijing, China
Jian Li , Ye Xu , Aimin Zang , Yunong Gao , Quanli Gao , Yanqiao Zhang , Dong Wang , Jianming Xu , Ying Yuan , Haiping Jiang , Jieer Ying , Chunmei Shi , Yanhong Deng , Jing Wang , Tianshu Liu , Yi Huang , Yaling Xu , Yidi Wang , Cong Fei , Lin Shen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Cancer Disparities
Clinical Trial Registration Number
NCT03736889
DOI
10.1200/JCO.2022.40.4_suppl.001
Abstract #
1
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable ormetastatic microsatellite instability-high/mismatch repair deficient solid tumors.
First Author: Jian Li
Poster
2023 ASCO Annual Meeting
MyTACTIC: Afficacy and safety of atezolizumab (atezo) + chemotherapy (chemo) in patients (pts) with advanced unresectable/metastatic solid tumors with high tumor mutational burden (TMB-H) or high microsatellite instability (MSI-H)/deficient mismatch repair (dMMR).
First Author: David R. Spigel
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations: Urothelial cancer cohort (SGNTUC-019).
First Author: Evan Y. Yu
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Clinical efficacy and biomarker analysis of pucotenlimab (HX008) in patients with previously treated advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A single-arm, multicenter, phase 2 study.
First Author: Bo Zhang